Jazz Pharma buys clinical-stage biotech company
Ireland-based Jazz Pharma has acquired Virginia-based Cavion in a deal that values the clinical-stage biotech company at up to $312.5 million.
Eli Lilly unit accuses Alzheimer's institute of ‘malicious’ patent prosecution
Avid Radiopharmaceuticals, a subsidiary of Eli Lilly, has taken the Alzheimer's Institute of America to court over its “malicious” prosecution of a patent infringement case.
Allergan says rivals using trade secrets disclosed by USITC order
Allergan has filed a motion asking for its “trade secrets” to be removed from evidence in a dispute over its wrinkle treatment, Botox.
Sandoz to appeal against Amgen biosimilar ruling
Sandoz has confirmed that it plans to appeal against a decision that upheld the validity of two of Amgen’s patents for its arthritis treatment Enbrel, effectively blocking the launch of Sandoz’s biosimilar version.
Fed Circ affirms Eli Lilly victories over cancer drugs
The US Court of Appeals for the Federal Circuit last week affirmed two findings that Dr Reddy’s and Hospira had infringed Eli Lilly’s cancer drug Alimta.
Bayer buys BlueRock to build cell therapy expertise
Bayer is set to acquire the rest of BlueRock Therapeutics, in a deal that values the Massachusetts-based cell therapy company at $1 billion.
NHS to receive £250m for new AI lab
The NHS will receive a £250 million investment to develop a new National AI Lab, which will use the technology to improve patient health, the UK government has announced.
FTC demands Boston Scientific divest business amid $4.2bn deal
The US Federal Trade Commission is requiring medical device maker Boston Scientific to divest business, as part of a settlement resolving antitrust charges related to its acquisition of UK-based healthcare company BTG.
Akebia Therapeutics and Par Pharma settle Auryxia suit
A subsidiary of Akebia Therapeutics has entered into a settlement agreement with Endo-owned Par Pharmaceutical.
Fed Circ backs ITC on E. coli patent dispute
The US Court of Appeals for the Federal Circuit yesterday, August 6, affirmed a US International Trade Commission decision to uphold a patent related to E. coli bacteria.
